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The supplier of Mitomycin C (Kyowa Hakko) was invited to
respond to the above Letter to the Editor.
In their Letter to the Editor, Yoshimoto and colleagues conclude
that 'MMC should be used with caution whatever the reason for its
increase in toxicity'. We feel apprehensive, however, that 'the
increase in toxicity' as argued by the authors might be subjective
rather than objective for the following reasons:
1. Quality control of MMC.
We are confident that the manufacture of MMC has been consis-
tently carried out under stringent quality control. Our MMC has
passed the inspection of the MCA (UK) and the FDA (USA) as
raw material and of the MCA as a pharmaceutical product. The
authors cited test results of the quality, in vitro activity and in vivo
marrow depression of MMC. The tests were conducted by our
company due to the repeated requests of Dr Yoshimoto and his
colleagues, who suspected the change of MMC itself as the cause
of the claimed increase in toxicity. We have disclosed our test
results to them, which showed, as they cite, no difference between
production lots of MMC manufactured in different years.
Moreover, our database covering all adverse reaction reports
within Japan during the controversial period reveals no increase of
severe marrow depression with MMC. Therefore, Kyowa Hakko
does not accept any association between the quality of MMC and
an increase or enhancement of marrow depression.
2. Is the claimed increase related to data analysis?
The authors list patient age, disease stage and dose or dosing
schedule as possible covariates. The patients with previous treat-
ment with anticancer drugs and those with a past history of
diseases that might affect bone marrow function were excluded
according to the figure legend. However, other covariates such as
sampling frequency and interval could be important in interpreting
the data. Yoshimoto et al have not presented the sampling
frequency in a particular period after administration (such as until
the next CMF therapy) or sampling interval in the period during
which blood cells are expected to reach true nadir.
We invite Yoshimoto and his co-authors to provide their raw
data for analysis by a medical statistician.
Overall, we do not consider that there is genuine evidence that
MMC has caused an increase of adverse reactions.
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